Trial Profile
A Phase II Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer ( RCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms DAST
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals Inc.
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 10 May 2019 This trial was completed in France (end date: 2019-04-02), according to European Clinical Trials Database.
- 30 Apr 2019 This trial was completed in Finland (end date: 2019-04-02), according to European Clinical Trials Database.